Heart HealthResearch PaperOpen Access

Leonurine blocks STING in heart endothelial cells and protects mice from doxorubicin cardiotoxicity

A plant alkaloid binds STING at TYR261 and breaks an endothelial-cardiomyocyte injury loop, preserving heart function in doxorubicin-treated mice.

Saturday, November 21, 2026 0 views
Published in Adv Sci (Weinh)
A mouse heart cross-section stained with Masson trichrome on a microscope slide under a lab microscope

Summary

In mice and cultured cells, the authors identify the cells lining cardiac blood vessels as early sensors of doxorubicin injury. Doxorubicin activates endothelial cGAS-STING signaling, triggering inflammatory cell death and the release of vesicles that damage mitochondria in neighboring heart muscle cells. The plant alkaloid leonurine binds STING at TYR261 and interrupts this injury loop; the authors also report direct protection of heart muscle cell mitochondria and preservation of cardiac function in mice. The excerpt does not establish a survival benefit or efficacy in patients.

Detailed Summary

Doxorubicin can cause dose-dependent cardiomyopathy that progresses to heart failure. This mouse and cell study identifies an upstream source of injury: the cells lining cardiac blood vessels are among the first to encounter circulating doxorubicin and can transmit damage to neighboring heart muscle cells.

The authors report that doxorubicin activates cGAS-STING signaling in cardiac vascular endothelial cells. They implicate the STING/NF-κB/NLRP3 pathway: NLRP3 inflammasome activation triggers pyroptosis, an inflammatory form of cell death, and endothelial cells release extracellular vesicles that impair cardiomyocyte mitochondria. The authors describe this communication between the two cell types as a self-perpetuating injury loop.

Leonurine, an alkaloid from Leonurus japonicus, reportedly binds non-covalently to TYR261 on STING. It blocks both the assembly of STING molecules into oligomers and the formation of a STING-TBK1 complex. The authors identify endothelial STING inhibition as the primary protective mechanism and report a second effect directly on cardiomyocyte mitochondria.

In the mouse model, all groups except controls received a 20 mg/kg tail-vein injection of doxorubicin. The four-week design included leonurine at 5, 10 or 20 mg/kg/day and separate pravastatin and C-176 groups. The authors report preservation of cardiac function, but the excerpt ends in Methods §2.11, before the results or figures. Group sizes, functional measurements and effect sizes are therefore unavailable. The excerpt provides no survival result, patient outcomes or evidence about whether leonurine alters doxorubicin’s antitumor activity.

Key Findings

  • Endothelial mechanism: the authors identify cardiac vascular endothelial cells as early sensors of doxorubicin. Activation of cGAS-STING triggers NLRP3 inflammasome-mediated pyroptosis.
  • Cell-to-cell injury: endothelial cells release extracellular vesicles that impair mitochondria in neighboring heart muscle cells, propagating injury beyond the vessel lining.
  • Target engagement: leonurine reportedly binds STING non-covalently at TYR261, blocking both STING oligomerization and STING-TBK1 complex formation.
  • Two sites of protection: the authors report that leonurine primarily interrupts injury by inhibiting endothelial STING and also directly protects cardiomyocyte mitochondria.
  • Function and survival: the authors report preserved cardiac function in the doxorubicin mouse model. The excerpt supplies no group sizes, functional effect estimates or survival comparison.

Methodology

The methods identify wild-type and STING-knockout mice on a C57BL/6 background. Non-control groups received a 20 mg/kg tail-vein injection of doxorubicin; four-week treatment groups included leonurine at 5, 10 or 20 mg/kg/day, pravastatin and C-176. Cell models included isolated mouse cardiac microvascular endothelial cells, human umbilical vein endothelial cells and H9C2 cells. The methods describe STING knockdown and overexpression, extracellular vesicle isolation, Western blotting, co-immunoprecipitation and a biotin-leonurine pull-down. The excerpt does not give group sizes or statistical tests.

Study Limitations

The evidence comes from mice and cultured cells, not treated patients. A single 20 mg/kg doxorubicin injection in mice does not reproduce repeated clinical dosing. The excerpt ends in Methods §2.11 and provides no group sizes, detailed results or figures with which to assess the magnitude of functional protection or inspect the evidence for the vesicle and TYR261 findings. Survival, long-term safety and effects on tumor response cannot be determined from the excerpt.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: